Deepened collaboration with Chinese partner

RNS Number : 7967X
Microsaic Systems plc
02 May 2019
 

02 May 2019

Microsaic Systems plc

 

("Microsaic" or the "Company")

 

Microsaic deepens collaboration with Chinese partner

 

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, announces that its Chinese partner, Unimicro Technologies Inc. ("Unimicro"), has completed further integrations of Microsaic's technology with Unimicro's separation technology.

 

Last year, Unimicro launched its micro capillary electrophoresis ("CE") equipment, integrated with Microsaic's unique small footprint MS. Typically a high-end technique, Unimicro's combined system brings protein characterisation to the bench chemist, in markets such as academia, pharmaceuticals and contract research organisations.

 

In March 2019, Unimicro announced that it has released the first in a series of micro-Liquid Chromatography ("LC") products, again integrated with Microsaic's technology. This will extend Unimicro's reach in China with micro LC-MS systems, a technique which has wide adoption in chemical and biological analysis, but which brings ease of use, a very small footprint, and large savings on solvent use to the end user. Further, the technique is ideally suited to high-value product purification, where there may be very little of the desired active compound.

 

Glenn Tracey, CEO of Microsaic, commented "I am very pleased with the progress between our two companies. Unimicro has consistently demonstrated its product innovation, with a clear vision of addressing the emerging needs in one of the world's most progressive economies. We are very excited as Unimicro continues to expand its product range, which integrates with our MS technology. Furthermore, we are looking forward to receiving one of Unimicro's PhD placements at our facility later in the year to work on joint applications and continue our spirit of collaboration."

 

Recently, Microsaic published its annual results for the year ending 2018, which showed a year on year doubling of unit sales, and with revenues up 69%. The Board believes that 2019 will be a year of significant growth in revenues, driven by the globally diverse partnerships signed in 2018, and the continued business development with new partners during 2019. Microsaic now has nine partners globally, including OEMs and distributors, and increasing interest in the far east, where innovative detection technology is particularly sought.

 

Enquiries:

 

 

Microsaic Systems plc

Glenn Tracey, CEO

Bevan Metcalf, FD

+44 (0) 1483 751 577

 

N+1 Singer (Nominated Adviser & Broker)

Shaun Dobson (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

 

+44 (0)20 7496 3000

IFC Advisory Ltd (Financial PR)

Graham Herring

Heather Armstrong

Florence Chandler

+44 (0)20 3934 6630

 

 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

 

Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.  

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAABMITMBIMBFL
UK 100

Latest directors dealings